Silence Therapeutics' shares jumped 29% after announcing positive topline results from the Phase 2 SANRECO trial for divesiran, which achieved a response rate of 88%. This significant advance suggests potential for further development, making it a key player in treating polycythemia vera.
Key Highlights
- The SANRECO trial achieved an 88% response rate versus 19% in the placebo group for polycythemia vera patients.
- Trading Volume surged to roughly $250.10 million, far above the average $16.40 million.
- The trial achieved a response rate of 88%, far exceeding the 19% observed in the placebo group.
The trial achieved a response rate of 88%, far exceeding the 19% observed in the placebo group. This remarkable performance is important as it indicates divesiran's promising potential in a space with few adequate treatment options, making it a compelling story for healthcare investors.
Positive Trial Results Announced
The SANRECO trial evaluated divesiran, a novel siRNA therapy, in 48 patients who are phlebotomy-dependent due to polycythemia vera. The primary endpoint was met with an impressive 88% of patients achieving a response, defined as maintaining hematocrit below 45% without the need for phlebotomies during the trial. Comparatively, only 19% of placebo recipients reached this benchmark, highlighting the efficacy of divesiran, which utilized dosages every six or twelve weeks.
These results bolster expectations about the upcoming Phase 3 trial planned for the first half of 2027.
Stock Movement and Volume
The trading volume soared to about $250.10 million, sharply contrasting with the daily average of approximately $16.40 million. Despite opening 39.7% higher than the previous close, SLN's stock has given back 7.6% of those gains through the session. The momentum generated by this trial news stands out, particularly given the stock's year-to-date increase of 150.9% and a 69.7% rise within the month.
Strong Technical Indicators
Silence Therapeutics is trading above key moving averages, including the 20-day average at $11.34 and the 50-day average at $9.41. The current 14-day RSI of 77.4 suggests bullish momentum, while the MACD at 0.88 indicates a positive trend above its signal line. Nearby price levels to watch include first support at $8.87 and first resistance at $12.15, which will be important in the coming days as investors reassess reaction to recent developments.
Future Roadmap
Silence Therapeutics will initiate its Phase 3 trial evaluating divesiran's efficacy as a treatment for polycythemia vera in 2027. This marks a critical juncture for the company, suggesting the potential to further establish divesiran as a best-in-class treatment for patients with few existing therapeutic options. Investors should monitor upcoming announcements regarding the trial’s design and further data disclosures expected from the ongoing studies.
Peers Moving on This News
- Silence Therapeutics PLC (SLNCF) up 164.0%
- Autolus Therapeutics PLC (AUTL) up 1.4%
- Bicycle Therapeutics PLC (BCYC) up 1.9%
Analysis based on the Form 8-K filed 10 August 2026.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making Investment decisions.



_11_19_2026_08_18_32_669904.jpg)
_11_19_2026_08_15_48_200775.jpg)

Please wait processing your request...